Combined COX-2/PPARγ Expression as Independent Negative Prognosticator for Vulvar Cancer Patients
Abstract
Share and Cite
Ansorge, N.; Dannecker, C.; Jeschke, U.; Schmoeckel, E.; Mayr, D.; Heidegger, H.H.; Vattai, A.; Burgmann, M.; Czogalla, B.; Mahner, S.; et al. Combined COX-2/PPARγ Expression as Independent Negative Prognosticator for Vulvar Cancer Patients. Diagnostics 2021, 11, 491. https://doi.org/10.3390/diagnostics11030491
Ansorge N, Dannecker C, Jeschke U, Schmoeckel E, Mayr D, Heidegger HH, Vattai A, Burgmann M, Czogalla B, Mahner S, et al. Combined COX-2/PPARγ Expression as Independent Negative Prognosticator for Vulvar Cancer Patients. Diagnostics. 2021; 11(3):491. https://doi.org/10.3390/diagnostics11030491
Chicago/Turabian StyleAnsorge, Nadine, Christian Dannecker, Udo Jeschke, Elisa Schmoeckel, Doris Mayr, Helene H. Heidegger, Aurelia Vattai, Maximiliane Burgmann, Bastian Czogalla, Sven Mahner, and et al. 2021. "Combined COX-2/PPARγ Expression as Independent Negative Prognosticator for Vulvar Cancer Patients" Diagnostics 11, no. 3: 491. https://doi.org/10.3390/diagnostics11030491
APA StyleAnsorge, N., Dannecker, C., Jeschke, U., Schmoeckel, E., Mayr, D., Heidegger, H. H., Vattai, A., Burgmann, M., Czogalla, B., Mahner, S., & Fuerst, S. (2021). Combined COX-2/PPARγ Expression as Independent Negative Prognosticator for Vulvar Cancer Patients. Diagnostics, 11(3), 491. https://doi.org/10.3390/diagnostics11030491

